Common drug interactions leading to adverse drug events in the intensive care unit: Management and pharmacokinetic considerations

被引:42
作者
Papadopoulos, John [1 ,2 ]
Smithburger, Pamela L. [3 ]
机构
[1] NYU, Arnold & Marie Schwartz Coll Pharm, New York, NY 10012 USA
[2] NYU, Div Pharmacotherapy, New York, NY USA
[3] Univ Pittsburgh, Sch Pharm, Med Intens Care Unit Clin Specialist, Med Ctr, Pittsburgh, PA USA
关键词
drug interactions; drug-drug interactions; drug-disease state interactions; drug-laboratory interactions; inducers; inhibitors; pharmacokinetics; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LONG QT SYNDROME; ALPHA-1-ACID GLYCOPROTEIN; P-GLYCOPROTEIN; IN-VITRO; PROTEIN-BINDING; DE-POINTES; WARFARIN; RISK; INTERFERENCE;
D O I
10.1097/CCM.0b013e3181de0acf
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Critically ill patients are predisposed to drug interactions because of the complexity of the drug regimens they receive in the intensive care setting. Drugs may affect the absorption, distribution, metabolism, and/or elimination of an object drug and consequently alter the intended pharmacologic response and potentially lead to an adverse event. Certain disease states that afflict critically ill patients may also amplify an intended pharmacologic response and potentially result in an unintended effect. A team approach is important to identify, prevent, and address drug interactions in the intensive care setting and optimize patient outcomes. (Crit Care Med 2010; 38[Suppl.]:S126-S135)
引用
收藏
页码:S126 / S135
页数:10
相关论文
共 132 条
  • [1] Interaction between fluconazole and midazolam in intensive care patients
    Ahonen, J
    Olkkola, KT
    Takala, A
    Neuvonen, PJ
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1999, 43 (05) : 509 - 514
  • [2] INTERACTION OF CITRUS JUICES WITH FELODIPINE AND NIFEDIPINE
    BAILEY, DG
    SPENCE, JD
    MUNOZ, C
    ARNOLD, JMO
    [J]. LANCET, 1991, 337 (8736) : 268 - 269
  • [3] Upper gastrointestinal bleeding in patients with acute coronary syndromes - Clinical predictors and prophylactic role of proton pump inhibitors
    Barada, Kassem
    Karrowni, Wassef
    Abdallah, Mouhamad
    Shamseddeen, Wael
    Sharara, Ala I.
    Dakik, Habib A.
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (04) : 368 - 372
  • [4] Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: An analysis of outcomes in patients with elevated international normalized ratio (INR)
    Bartholomew, J
    Hursting, M
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2005, 19 (03) : 183 - 188
  • [5] *BAYER CORP, 2002, PROD INF CIPR CIPR
  • [6] *BAYER HLTH CAR, 2008, PROD INF AV MOX HYDR
  • [7] QUINIDINE AND DIGOXIN - AN IMPORTANT INTERACTION
    BIGGER, JT
    LEAHEY, EB
    [J]. DRUGS, 1982, 24 (03) : 229 - 239
  • [8] Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in β-Blocker Users
    Bijl, M. J.
    Visser, L. E.
    van Schaik, R. H. N.
    Kors, J. A.
    Witteman, J. C. M.
    Hofman, A.
    Vulto, A. G.
    van Gelder, T.
    Stricker, B. H. Ch
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (01) : 45 - 50
  • [9] Digoxin-Macrolide drug interaction
    Bizjak, ED
    Mauro, VF
    [J]. ANNALS OF PHARMACOTHERAPY, 1997, 31 (09) : 1077 - 1079
  • [10] *BOER ING PHARM, 2009, PROD INF AGGR ASP EX